Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | CNR2 | P34972 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | PLAU | P00749 | 1/20 | 0.51 |
| ▸ | ELANE | P08246 | 1/20 | 0.51 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8252233 | 0.90 | TRPV1 (0.58) | ALDH1A1KDM4ELMNANPC1HPGD | |
| SCHEMBL28308721 | 0.82 | HPGD (0.54) | MEN1KMT2AALDH1A1LMNARAB9A | |
| SCHEMBL14271130 | 0.82 | HTT (0.55) | MEN1KMT2AALDH1A1KDM4ELMNA | |
| SCHEMBL25372645 | 0.82 | MEN1 (0.57) | MEN1KMT2AHDAC8HDAC6ALDH1A1 | |
| SCHEMBL4510673 | 0.82 | SMN1; SMN2 (0.57) | MEN1KMT2AHDAC6ALDH1A1KDM4E | |
| Quinoline SCHEMBL27388892 | 0.82 | HDAC3 (0.47) | MEN1KMT2AALDH1A1KDM4ELMNA | |
| SCHEMBL12808988 | 0.81 | GAA (0.58) | MEN1KMT2AALDH1A1KDM4ELMNA | |
| SCHEMBL4928502 | 0.81 | HTT (0.73) | MEN1KMT2AALDH1A1LMNARAB9A | |
| SCHEMBL28308722 | 0.81 | KMT2A (0.55) | MEN1KMT2AHDAC8HDAC6ALDH1A1 | |
| SCHEMBL13527480 | 0.81 | HDAC2 (0.61) | HDAC8HDAC6ALDH1A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109912603-B | Practical method for synthesizing novel bioactive molecules by using N-methoxyamide as nitrogen source | 苏州大学 | 2021-08-03 | — | — | CN | disclosed |
| EP-3408256-A1 | INDANE DERIVATIVES AS MGLUR7 MODULATORS | Takeda Pharmaceutical Company Limited (JP) | 2018-12-05 | — | — | EP | disclosed |
| WO-2017131221-A1 | INDANE DERIVATIVES AS MGLUR7 MODULATORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-03 | — | — | WO | disclosed |
| US-7919617-B2 | Cytokine inhibitors | iTherX Pharmaceuticals Inc. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7897599-B2 | Cytokine inhibitors | iTherX Pharmaceuticals Inc. (US) | 2011-03-01 | — | — | US | disclosed |
| US-20100273797-A1 | ALPHA-KETOAMIDES AND DERIVATIVES THEREOF | ITHERX PHARMACEUTICALS, INC. | 2010-10-28 | — | — | US | disclosed |
| US-7749999-B2 | Alpha-ketoamides and derivatives thereof | ITHERX PHARMACEUTICALS, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20100093734-A1 | CYTOKINE INHIBITORS | ITHERX PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100093735-A1 | CYTOKINE INHIBITORS | ITHERX PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-7648997-B2 | Immunomodulators for inducing cytokine biosynthesis, for treatment of diseases including viral and neoplastic diseases; 1-[3-(Aminooxy)propyl]-2-propyl-1H-imidazo[4,5-c]quinolin-4-amine; N-[3-(4-Amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)propoxy]cyclopropanecarboxamide | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-20080114019-A1 | Hydroxylamine Substituted Imidazoquinolines | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-05-15 | — | — | US | disclosed |
| US-20080114019-A1 | Hydroxylamine Substituted Imidazoquinolines | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-05-15 | — | — | US | disclosed |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
| US-20050107399-A1 | Cytokine inhibitors | KEMIA, INC. | 2005-05-19 | — | — | US | disclosed |
| US-6743794-B2 | MULTIDRUG RESISTANCE PROTEIN; CANCER; 3-(9-CHLORO-3-METHYL-4-OXO-5H-ISOXAZOLO(4,3-C)QUINOLIN-5-YL)) CYCLOHEXYL)-2-PIPERIDYLACETAMIDE | ELI LILLY AND COMPANY | 2004-06-01 | — | — | US | disclosed |
| WO-2003061595-A2 | ANTIBODIES AGAINST AND COMPOSITIONS CONTAINING NEW AMPHETAMINE DERIVATIVES | DRUGABUSE SCIENCES S.A.S. (FR) | 2003-07-31 | — | — | WO | disclosed |
| EP-0580502-B1 | 3-(Hydroxybenzylidenyl)-indoline-2-ones and pharmaceutical compositions containing them | ADIR (FR) | 1998-09-02 | — | — | EP | disclosed |
| US-5382593-A | Antioxidants or anticoagulants | ADIR ET COMPAGNIE (FR) | 1995-01-17 | — | — | US | disclosed |
| EP-0580502-A1 | 3-(Hydroxybenzylidenyl)-indoline-2-ones and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1994-01-26 | — | — | EP | disclosed |
| EP-0017970-B1 | NOVEL BETA-LACTAM DERIVATIVES AND PROCESS FOR PRODUCTION THEREOF | SANRAKU-OCEAN CO., LTD. (JP) | 1982-07-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107399-A1 | Cytokine inhibitors | TNF, IL1RN, IL1A | MEN1 4312/4885KMT2A 3812/4885HDAC8 926/4885 |
| US-20100093734-A1 | CYTOKINE INHIBITORS | TNF, IL1RN, IL1A | MEN1 4312/4885KMT2A 3812/4885HDAC8 926/4885 |
| US-20100273797-A1 | ALPHA-KETOAMIDES AND DERIVATIVES THEREOF | TNF, IL1A, IL1B | MEN1 4645/4885KMT2A 382/4885HDAC8 77/4885 |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | MEN1 734/4885KMT2A 693/4885HDAC8 4616/4885 |
| US-20080114019-A1 | Hydroxylamine Substituted Imidazoquinolines | IFNG, IRF3, IL2 | MEN1 4072/4885KMT2A 1181/4885HDAC8 713/4885 |
| US-20100093735-A1 | CYTOKINE INHIBITORS | TNF, IL1RN, IL1A | MEN1 4312/4885KMT2A 3812/4885HDAC8 926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.